Bringing you live news and features since 2006 

AlphaCentric launches LifeSci Healthcare Fund focused on biotech and healthcare sectors

RELATED TOPICS​

AlphaCentric has launched the AlphaCentric LifeSci Healthcare Fund (LYFIX), a new mutual fund will focus on investing in biotech and healthcare equities. 

AlphaCentric has launched the AlphaCentric LifeSci Healthcare Fund (LYFIX), a new mutual fund will focus on investing in biotech and healthcare equities. The fund draws on expertise of more than 20 PhDs and MDs and the scientific and investment backgrounds of the portfolio management team to identify companies with groundbreaking scientific research that the team believes can achieve the Fund’s investment objective of long-term capital appreciation. The Fund is sub-advised by LifeSci Fund Management, a research-driven investment bank and asset manager with deep domain expertise in life sciences.

LYFIX’s is designed to outperform other funds in its sector by leveraging this unique combination of scientific and investment experience to invest in the life sciences and healthcare sectors. The Fund’s investment strategy focuses on science-driven biotechnology and pharmaceutical companies that address high, unmet medical needs. Equity positions are concentrated on the following categories: biotech and pharmaceutical, health care facilities and services and medical equipment and device industries.

The portfolio is managed by Mark Charest, PhD. A former practicing molecular chemist and inventor on eight drug patents turned Wall Street trader, Charest has spent more than a decade investing in healthcare. He received a PhD and MS in chemistry and chemical biology from Harvard University and was a National Science Foundation Graduate Research Fellow. His background provides a specialized knowledge and acute ability to assess investment opportunities in this sector.
 
“Capital flowing into the healthcare and biotech sectors has exploded, boosted by promising advances in genomics and other scientific breakthroughs,” says Mark Kamies, co-founder of AlphaCentric. “The tremendous opportunity and challenge for investors is to figure out which companies possess truly game changing research, products and services that will result in strong stock performance. When new science and biotechnology are introduced to the market, it takes a specialised knowledge to assess its future and viability. We are tapping such expertise with Mark Charest and the LifeSci team, and are proud to offer their expertise and this focused strategy to investors.”
 

Latest News

Saving and investing app, Moneybox, has doubled the number of ETFs available on the platform, in the light of ‘growing..
Global X ETFs has announced the appointment of Ryan O'Connor as its Chief Executive Officer effective as of April 8, 2024. ..
Value-driven structured credit investing firm, Angel Oak Capital Advisors, LLC, has announced the completed conversions of two of its mutual..
Confidence in the continuing strength of bitcoin and Ethereum is driving wider interest in altcoins and other digital assets, according..

Related Articles

Graham MacKenzie, Toronto Stock Exchange
The evolution of ETFs has been a multi-decade experience for Toronto Stock Exchange says Graham MacKenzie, managing director, Exchange Traded...
Frank Koudelka, State Street Global Services
ETF data provider and ETF Express data partner, Trackinsight, has published its Global ETF Survey 2024 Report: ‘50+ Charts on...
Cryptocurrencies
Matteo Greco, Research Analyst at Fineqia International writes that bitcoin (BTC) ended the week at approximately USD52,150, showing a notable...
US Distribution Awards trophies
The winners of the first US ETF Distribution Awards at the Exchange conference, hosted by ETF Express and sponsored by...
Subscribe to the ETF Express newsletter

Subscribe for access to our weekly newsletter, newsletter archive, updates on the site and exclusive email content.

Marketing by